Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

ClinicalTrials.gov ID: NCT02161718

Public ClinicalTrials.gov record NCT02161718. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).

Study identification

NCT ID
NCT02161718
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
300 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Jan 10, 2017
Completion
Jan 31, 2017
Last update posted
Oct 7, 2021

2014 – 2017

United States locations

U.S. sites
58
U.S. states
20
U.S. cities
53
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72211
Alkermes Investigational Site Springdale Arkansas 72764
Alkermes Investigational Site Anaheim California 92805
Alkermes Investigational Site Culver City California 90230
Alkermes Investigational Site Garden Grove California 92845
Alkermes Investigational Site Irvine California 92617
Alkermes Investigational Site La Jolla California 92037
Alkermes Investigational Site Long Beach California 90822
Alkermes Investigational Site National City California 91950
Alkermes Investigational Site Oakland California 94612
Alkermes Investigational Site Oceanside California 92056
Alkermes Investigational Site Orange California 92868
Alkermes Investigational Site San Diego California 92123
Alkermes Investigational Site San Francisco California 94121
Alkermes Investigational Site Torrance California 90502
Alkermes Investigational Site Washington D.C. District of Columbia 20016
Alkermes Investigational Site Fort Lauderdale Florida 33308
Alkermes Investigational Site Leesburg Florida 34748
Alkermes Investigational Site Maitland Florida 32751
Alkermes Investigational Site Miami Florida 33122
Alkermes Investigational Site Miami Florida 33136
Alkermes Investigational Site North Miami Florida 33021
Alkermes Investigational Site Oakland Park Florida 33334
Alkermes Investigational Site Orlando Florida 32803
Alkermes Investigational Site Tampa Florida 33613
Alkermes Investigational Site Atlanta Georgia 30308
Alkermes Investigational Site Augusta Georgia 30912
Alkermes Investigational Site Decatur Georgia 30030
Alkermes Investigational Site Chicago Illinois 60640
Alkermes Investigational Site Hoffman Estates Illinois 60169
Alkermes Investigational Site Oak Brook Illinois 60523
Alkermes Investigational Site Shreveport Louisiana 71101
Alkermes Investigational Site Worcester Massachusetts 01605
Alkermes Investigational Site Flowood Mississippi 39232
Alkermes Investigational Site Creve Coeur Missouri 63141
Alkermes Investigational Site Kansas City Missouri 64108
Alkermes Investigational Site St Louis Missouri 63118
Alkermes Investigational Site Las Vegas Nevada 89102
Alkermes Investigational Site Claremont New Hampshire 03743
Alkermes Investigational Site Nashua New Hampshire 03060
Alkermes Investigational Site Neptune City New Jersey 07753
Alkermes Investigational Site Cedarhurst New York 11516
Alkermes Investigational Site Jamaica New York 11423
Alkermes Investigational Site New York New York 10021
Alkermes Investigational Site New York New York 10032
Alkermes Investigational Site New York New York 10035
Alkermes Investigational Site Rochester New York 14642
Alkermes Investigational Site Staten Island New York 10312
Alkermes Investigational Site Dayton Ohio 45417
Alkermes Investigational Site Oklahoma City Oklahoma 73112
Alkermes Investigational Site Scranton Pennsylvania 18503
Alkermes Investigational Site Charleston South Carolina 29401
Alkermes Investigational Site Charleston South Carolina 29407
Alkermes Investigational Site Charleston South Carolina 29425
Alkermes Investigational Site Austin Texas 78754
Alkermes Investigational Site Dallas Texas 75214
Alkermes Investigational Site DeSoto Texas 75115
Alkermes Investigational Site Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02161718, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02161718 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →